Journal of Hepatology
Volume 51, Issue 1 , Pages 4-7 , July 2009

What offers the best prediction of sustained virologic response during combination therapy with interferon and ribavirin: Viral dynamics, viral levels at certain time points, or a combination of both?

  • Ola Weiland

      Affiliations

    • Corresponding Author InformationTel.: +46 8 58580000; fax: +46 8 58581916.

References 

  1. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group. Lancet. 1998;351:83–87
  2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975–982
  3. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140:346–355
  4. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001;358:958–965
  5. Neumann AU, Lam NP, Dahari H, Davidian M, Wiley TE, Mika BP, et al. Differences in viral dynamics between genotypes 1 and 2 of hepatitis C virus. J Infect Dis. 2000;182:28–35
  6. Neumann AU, Lam NP, Dahari H, Gretch DR, Wiley TE, Layden TJ, et al. Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon-alpha therapy. Science. 1998;282:103–107
  7. Läkemedelsbehandling av kronisk hepatit C hos vuxna och barn – uppdaterad rekommendation. Information från Läkemedelsverket (Information from the Swedish medical Product Agency) 2008;6:14–26.
  8. Ferenci P, Fried MW, Shiffman ML, Smith CI, Marinos G, Goncales FL, et al. Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin. J Hepatol. 2005;43:425–433
  9. Dalgard O, Bjoro K, Ring-Larsen H, Bjornsson E, Holberg-Petersen M, Skovlund E, et al. Pegylated interferon alfa and ribavirin for 14 versus 24weeks in patients with hepatitis C virus genotype 2 or 3 and rapid virological response. Hepatology. 2008;47:35–42
  10. Ferenci P, Laferl H, Scherzer TM, Gschwantler M, Maieron A, Brunner H, et al. Peginterferon alfa-2a and ribavirin for 24weeks in hepatitis C ype 1 and 4 patients with rapid virological response. Gastroenterology. 2008;135:451–458
  11. Jensen DM, Morgan TR, Marcellin P, Pockros PJ, Reddy KR, Hadziyannis SJ, et al. Early identification of HCV genotype 1 patients responding to 24weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology. 2006;43:954–960
  12. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Randomized comparison of 12 or 24weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2/3 infection. Hepatology. 2008;47:1837–1845
  13. Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, et al. Determinants of relapse after a short (12weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection. Hepatology. 2009;49:358–363
  14. Zeuzem S, Buti M, Ferenci P, Sperl J, Horsmans Y, Cianciara J, et al. Efficacy of 24weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. J Hepatol. 2006;44:97–103
  15. Lagging M, Langeland N, Pedersen C, Farkkila M, Buhl MR, Morch K, et al. Weight-adjusted dosing of ribavirin and importance of hepatitis C virus RNA below 1000IU/mL by day 7 in short-term peginterferon therapy for chronic genotype 2/3 hepatitis C virus infection. Hepatology. 2008;48:695
  16. Weiland O, Hollander A, Mattsson L, Glaumann H, Lindahl K, Schvarcz R, et al. Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirin. J Viral Hepat. 2008;15:641–645
  17. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders. Hepatology. 2007;46:1688–1694
  18. Sanchez-Tapias JM, Diago M, Escartin P, Enriquez J, Romero-Gomez M, Barcena R, et al. Peginterferon-alfa2a plus ribavirin for 48 versus 72weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment. Gastroenterology. 2006;131:451–460
  19. Berg T, von Wagner M, Nasser S, Sarrazin C, Heintges T, Gerlach T, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72weeks of peginterferon-alfa-2a plus ribavirin. Gastroenterology. 2006;130:1086–1097
  20. Jessner W, Gschwantler M, Steindl-Munda P, Hofer H, Watkins-Riedel T, Wrba F, et al. Primary interferon resistance and treatment response in chronic hepatitis C infection: a pilot study. Lancet. 2001;358:1241–1242
  21. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long-term response among patients infected with genotype-1 hepatitis C virus. J Infect Dis. 2004;189:964–970
  22. Lindh M, Alestig E, Arnholm B, Eilard A, Hellstrand K, Lagging M, et al. Response prediction and treatment tailoring for chronic hepatitis C virus genotype 1 infection. J Clin Microbiol. 2007;45:2439–2445
  23. Neumann AU, Pianko S, Zuezem S, Yoshida EM, Benhamou Y, Mishan M, et al. Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C. J Hepatol. 2009;51:21–28
  24. Anonymous. NIH consensus development conference statement:management of hepatitis C 2002 (June 10–12, 2002). Hepatology 2002;36(Suppl. 1):S3–S20.
  25. Soriano V, Peters MG, Zeuzem S. New therapies for hepatitis C virus infection. Clin Infect Dis. 2009;48:313–320
  26. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123:1061–1069

☆ The author has declared that he has received grants from Schering-Plough, Roche, Tibotec and Swedish Orphans and has declared that that he has been on the Speakers Bureau for Schering-Plough, Roche, Tibotec, Swedish Orphans, Bristol Myers Squibb, Gilead and Novartis. He also declared that he is the P.I. in Sweden for studies run by Roche, Schering-Plough, Merch Sharp; Dome Limited and Swedish Orphans.

PII: S0168-8278(09)00240-2

doi: 10.1016/j.jhep.2009.04.002

Journal of Hepatology
Volume 51, Issue 1 , Pages 4-7 , July 2009

Article Tools